SCHEMBL2869320

SCHEMBL2869320

O=S(OCO)OCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16299498 0.85
SCHEMBL9005251 0.74
SCHEMBL127456 0.72 TSHR (0.39)
SCHEMBL29002914 0.72
SCHEMBL9751404 0.69
Water SCHEMBL30631870 0.69
Water SCHEMBL30631869 0.67
SCHEMBL22440711 0.67 CYP2C19 (0.32)
SCHEMBL22440705 0.65 GAA (0.33)
SCHEMBL23829590 0.62 TSHR (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0576686-B1 CELL DAI ICHI KOGYO SEIYAKU CO LTD (JP) 2001-10-10 EP claimed
EP-2095833-B1 Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices CARDINAL HEALTH 515 GMBH (CH) 2019-08-28 EP disclosed
US-9603980-B2 Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices CARDINAL HEALTH SWITZERLAND 515 GmbH (CH) 2017-03-28 US disclosed
EP-3056229-A2 THE LOCAL ADMINISTRATION OF A COMBINATION OF RAPAMYCIN AND 17 BETA-ESTRADIOL FOR THE TREATMENT OF VULNERABLE PLAQUE Cordis Corporation (US) 2016-08-17 EP disclosed
US-9402804-B2 Injectable formulations of taxanes for cad treatment CARDINAL HEALTH SWITZERLAND 515 GmbH (CH) 2016-08-02 US disclosed
EP-1591108-B1 Solution formulations of sirolimus and its analogs for CAD treatment CORDIS CORP (US) 2016-03-16 EP disclosed
US-8871240-B2 Rapamycin coated expandable devices CORDIS CORPORATION 2014-10-28 US disclosed
US-8784860-B2 Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease CORDIS CORPORATION 2014-07-22 US disclosed
US-8747881-B2 Intraluminal medical devices in combination with therapeutic agents CORDIS CORPORATION 2014-06-10 US disclosed
US-20140004254-A1 THERAPEUTIC AGENT ELUTION CONTROL PROCESS CORDIS US CORP 2014-01-02 US disclosed
EP-1591108-A2 Solution formulations of sirolimus and its analogs for CAD treatment Cordis Corporation (US) 2005-11-02 EP disclosed
US-20050232964-A1 Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices WYETH 2005-10-20 US disclosed
US-20050232965-A1 Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque WYETH 2005-10-20 US disclosed
EP-1586337-A2 The local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque Cordis Corporation (US) 2005-10-19 EP disclosed
EP-1586338-A2 The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices Cordis Corporation (US) 2005-10-19 EP disclosed
US-20050222191-A1 Solution formulations of sirolimus and its analogs for CAD treatment WYETH 2005-10-06 US disclosed
US-20050004663-A1 Heparin barrier coating for controlled drug release WYETH 2005-01-06 US disclosed
EP-0576686-B1 CELL DAI ICHI KOGYO SEIYAKU CO LTD (JP) 2001-10-10 EP disclosed
CN-1045710-C Pesticidal 1-arylimidazoles RHONE POULENC AGROCHIMIE (FR) 1999-10-20 CN disclosed
CN-1046898-A 1-Aryimidazole insecticides RHONE POULENC AGROCHIMIE (FR) 1990-11-14 CN disclosed